3 Undervalued Pharmaceuticals Stocks for Monday, March 25
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, March 25 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Akanda Corp., through its subsidiaries, operates as early-stage cannabis company in Mexico. It is involved in medical cannabis cultivation, manufacturing, and sale; and leasing and/or rental of fiber optic networks and telecommunication towers. The company is based in Toronto, Canada.
Commentary & Analysis
Is Akanda Corp (AKAN) Stock a Good Investment?
Learn more about Akanda Corp's (AKAN) stock grades for Growth and determine whether this Pharmaceuticals stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | AKAN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.1 | $618.0 | 2% |
|
| Shares Out (Mil) | 0.1 | 44.8 | 1% |
|
| Institutional Ownership | 14.5% | 85.3% | 8% |
|
| Float (Mil) | 0.5 | 47.4 | 1% |
|
| Beta | na | 0.70 | na |
|
| Avg Daily Volume (000s) | 2,720 | 390 | 86% |
|
| Price Change (52-week) |
(95.8%) | 68.6% | 2% |
|
| Growth | AKAN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (81.8%) | (1.6%) | 3% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AKAN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $291 | 1% |
|
| Net Income (TTM) (Mil) | ($46) | ($11) | 17% |
|
| EPS (TTM) | ($662.218) | ($0.700) | 0% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($6) | 23% |
|
| Net Cash Flow (TTM) (Mil) | ($3) | $5 | 36% |
|
| Long-Term Debt (Q1) (Mil) | $12 | $6 | 29% |
|
| Enterprise Value (Q1) (Mil) | $19 | $450 | 11% |
|
| Valuation | AKAN | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.78 | na |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AKAN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (60.5%) | 67.0% | 2% |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (647.1%) | (22.4%) | 0% |
|
| ROE | na | (20.2%) | na |
|
| Liabilities to Assets | 293.5% | 32.2% | 99% |
|
| F-Score | 1 | 3 | na |
|
Akanda Corp. did not pass any screens on 8/20/2026.
